Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer
暂无分享,去创建一个
R. Labianca | E. Oki | T. Yamanaka | V. Georgoulias | A. Grothey | I. Boukovinas | F. Ou | Q. Shi | T. Yoshino | S. Lonardi | J. Paul | A. Sobrero | J. Meyers | R. Kerr | K. Yamazaki | T. Iveson | M. Saunders | G. Rosati | I. Souglakos | A. Harkin | N. H. Hollander | F. Galli
[1] E. Oki,et al. Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer , 2019, JAMA oncology.
[2] A. Briggs,et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial , 2018, The Lancet. Oncology.
[3] R. Labianca,et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer , 2018, The New England journal of medicine.
[4] F. D. De Braud,et al. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Salazar,et al. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M Buyse,et al. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. , 2011, European journal of cancer.
[7] R. Labianca,et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] D. Sargent,et al. Revised TN categorization for colon cancer based on national survival outcomes data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] T. Hickish,et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Labianca,et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Kerr,et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.
[12] N. Petrelli,et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] T. Hickish,et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.